The only FDA-approved drugs currently available for DDR1 and BCR/ABL proteins are the BCR-ABL family of multi-tyrosine kinase inhibitors; however, DDR1- and BCR-ABL-specific compounds are constantly being developed (82, 122), and a combination of DDR1-, BCR-ABL1-, and EGFR/ERBB2-4-specific drugs could co-operate, synergize, and open a new paradigm for future cancer therapeutics. The gene discussed is BCR; the disease is cancer.